GlaxoSmithKline S.A.E (EGX:BIOC)

GlaxoSmithKline S.A.E Statistics

Total Valuation

EGX:BIOC has a market cap or net worth of EGP 3.18 billion. The enterprise value is 3.04 billion.

Market Cap	3.18B
Enterprise Value	3.04B

Important Dates

The next estimated earnings date is Thursday, August 14, 2025.

Earnings Date	Aug 14, 2025
Ex-Dividend Date	Jul 18, 2024

Share Statistics

EGX:BIOC has 83.51 million shares outstanding.

Current Share Class	83.51M
Shares Outstanding	83.51M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	2.43M

Valuation Ratios

The trailing PE ratio is 13.15.

PE Ratio	13.15
Forward PE	n/a
PS Ratio	0.97
PB Ratio	1.51
P/TBV Ratio	1.51
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 5.78, with an EV/FCF ratio of -14.71.

EV / Earnings	12.56
EV / Sales	0.93
EV / EBITDA	5.78
EV / EBIT	6.45
EV / FCF	-14.71

Financial Position

The company has a current ratio of 1.59, with a Debt / Equity ratio of 0.04.

Current Ratio	1.59
Quick Ratio	0.29
Debt / Equity	0.04
Debt / EBITDA	0.16
Debt / FCF	-0.39
Interest Coverage	37.50

Financial Efficiency

Return on equity (ROE) is 12.13% and return on invested capital (ROIC) is 13.24%.

Return on Equity (ROE)	12.13%
Return on Assets (ROA)	6.51%
Return on Invested Capital (ROIC)	13.24%
Return on Capital Employed (ROCE)	20.33%
Revenue Per Employee	4.09M
Profits Per Employee	302,617
Employee Count	800
Asset Turnover	0.76
Inventory Turnover	1.94

Taxes

In the past 12 months, EGX:BIOC has paid 222.86 million in taxes.

Income Tax	222.86M
Effective Tax Rate	47.93%

Stock Price Statistics

The stock price has increased by +33.19% in the last 52 weeks. The beta is 0.93, so EGX:BIOC's price volatility has been similar to the market average.

Beta (5Y)	0.93
52-Week Price Change	+33.19%
50-Day Moving Average	38.26
200-Day Moving Average	38.04
Relative Strength Index (RSI)	37.85
Average Volume (20 Days)	85,343

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, EGX:BIOC had revenue of EGP 3.27 billion and earned 242.09 million in profits. Earnings per share was 2.90.

Revenue	3.27B
Gross Profit	880.28M
Operating Income	447.47M
Pretax Income	464.95M
Net Income	242.09M
EBITDA	488.59M
EBIT	447.47M
Earnings Per Share (EPS)	2.90

Balance Sheet

The company has 225.46 million in cash and 80.84 million in debt, giving a net cash position of 144.61 million or 1.73 per share.

Cash & Cash Equivalents	225.46M
Total Debt	80.84M
Net Cash	144.61M
Net Cash Per Share	1.73
Equity (Book Value)	2.11B
Book Value Per Share	25.25
Working Capital	1.42B

Cash Flow

In the last 12 months, operating cash flow was -108.62 million and capital expenditures -98.01 million, giving a free cash flow of -206.63 million.

Operating Cash Flow	-108.62M
Capital Expenditures	-98.01M
Free Cash Flow	-206.63M
FCF Per Share	-2.47

Margins

Gross margin is 26.91%, with operating and profit margins of 13.68% and 7.40%.

Gross Margin	26.91%
Operating Margin	13.68%
Pretax Margin	14.21%
Profit Margin	7.40%
EBITDA Margin	14.94%
EBIT Margin	13.68%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of 0.75, which amounts to a dividend yield of 1.97%.

Dividend Per Share	0.75
Dividend Yield	1.97%
Dividend Growth (YoY)	-80.00%
Years of Dividend Growth	n/a
Payout Ratio	28.78%
Buyback Yield	n/a
Shareholder Yield	2.02%
Earnings Yield	7.60%
FCF Yield	-6.49%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

EGX:BIOC has an Altman Z-Score of 2.48 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.48
Piotroski F-Score	3